ÉMÉva Monostori

Éva Monostori

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Éva Monostori has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • Roberta Fajka-Boja

    Institute of Genetics, Biological Research Center, Hungarian Academy of Sciences, Szeged, Hungary

    2 shared publications
  • Andrea Blaskó

    Biological Research Center, Hungarian Academy of Sciences, Szeged, Hungary

    1 shared publication
  • Beáta Hegyi

    Stem Cell Biology, National Blood Service, Budapest, Hungary

    1 shared publication
  • Enikő Szabó

    Institute of Genetics, Biological Research Center, Hungarian Academy of Sciences, Szeged, Hungary

    1 shared publication
  • Ferenc Uher

    Stem Cell Biology, National Blood Service, Budapest, Hungary

    1 shared publication
  • G Ion

    Lymphocyte Signal Transduction Laboratory, Institute of Genetics, Biological Research Center of Hungarian Academy of Sciences, Szeged H-6726, Hungary

    1 shared publication

Latest Publications

  • Open Access

    Identification of Galectin-1 as a Critical Factor in Function of Mouse Mesenchymal Stromal Cell-Mediated Tumor Promotion

    by Gábor János Szebeni, Éva Kriston-Pál, Péter Blazsó, Róbert László Katona, Julianna Novák, Enikő Szabó, Ágnes Czibula, Roberta Fajka-Boja, Beáta Hegyi, Ferenc Uher, et al.

    Bone marrow derived mesenchymal stromal cells (MSCs) have recently been implicated as one source of the tumor-associated stroma, which plays essential role in regulating tumor progression. In spite of the intensive research, the individual factors in MSCs controlling tumor progression have not been adequately defined. In the present study we have examined the role of galectin-1 (Gal-1), a protein highly expressed in tumors with poor prognosis, in MSCs in the course of tumor development. Co-transplantation of wild type MSCs with 4T1 mouse breast carcinoma cells enhances the incidence of palpable tumors, growth, vascularization and metastasis. It also reduces survival compared to animals treated with tumor cells alone or in combination with Gal-1 knockout MSCs. In vitro studies show that the absence of Gal-1 in MSCs does not affect the number of migrating MSCs toward the tumor cells, which is supported by the in vivo migration of intravenously injected MSCs into the tumor. Moreover, differentiation of endothelial cells into blood vessel-like structures strongly depends on the expression of Gal-1 in MSCs. Vital role of Gal-1 in MSCs has been further verified in Gal-1 knockout mice. By administering B16F10 melanoma cells into Gal-1 deficient animals, tumor growth is highly reduced compared to wild type animals. Nevertheless, co-injection of wild type but not Gal-1 deficient MSCs results in dramatic tumor growth and development. These results confirm that galectin-1 is one of the critical factors in MSCs regulating tumor progression.


  • How does it act when soluble? Critical evaluation of mechanism of galectin-1 induced T-cell apoptosis

    by Andrea Blaskó, Roberta Fajka-Boja, Gabriela Ion, Éva Monostori

    Galectin-1 (Gal-1), a mammalian lectin induces apoptosis of T lymphocytes. Contradictory data have resulted in confusing knowledge regarding mechanism of Gal-1 induced T-cell apoptosis. In this paper we aimed to resolve this controversy by comparing cell death induced by low (1.8 μM, lowGal-1) and high (18 μM, highGal-1) concentration of soluble Gal-1. We show that lowGal-1 and highGal-1 trigger phosphatidylserine exposure, generation of rafts and mitochondrial membrane depolarization. In contrast, lowGal-1 but not highGal-1 is dependent on the presence of p56lck and ZAP70 and activates caspase cascade. The results allow the conclusion that the cell-death mechanism strictly depends on the concentration of Gal-1.